A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
← catalyst calendarNCT07073079 · readout ≤ 499 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
250estimated
Sites
25
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-14 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Crohn's Disease
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants who Achieve Corticosteroids (CS) Free Remission
measured Month 12
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed